RYTHMOIRESEARCH
SMS Research Updates ↗

GILD / Healthcare

GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)

Company overview

GILEAD SCIENCES, INC. is an SEC-reporting issuer listed on NASDAQ under GILD. Its SEC industry description is Biological Products, (No Diagnostic Substances). This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Business segments

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Selected fundamentals

Annual reporting currency: USD. Financial amounts are in millions, except per-share figures and ratios.

Latest period 2025-12-31 · prior period 2024-12-31
Metric2025-12-312024-12-31Source filed
RevenueUSD 29,443mUSD 28,754m2026-02-24
Operating incomeUSD 10,022mUSD 1,662m2026-02-24
Net incomeUSD 8,510mUSD 480m2026-02-24
Diluted EPSUSD 6.78USD 0.382026-02-24
Operating cash flowUSD 10,019mUSD 10,828m2026-02-24
Capital expenditureUSD 563mUSD 523m2026-02-24
Free cash flowUSD 9,456mUSD 10,305m2026-02-24
Gross marginNot availableNot available2026-02-24
Operating margin34.04%5.78%2026-02-24

FCF = operating cash flow − purchases of property, plant and equipment. Missing tags remain unavailable. Standardized cash-flow comparisons are particularly limited for financial businesses.

Inspect original metric provenance
{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 29443000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 8510000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10022000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:OperatingIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 6.78,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10019000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 563000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 59023000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": 22703000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 18342000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 11813000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Annual earnings trend

Reported fiscal periods, not a live price chart.

Interactive chart loads in the browser. The full annual values are available below.

View all annual figures in a table
Period endRevenueNet incomeEPS
2025-12-31USD 29,443mUSD 8,510mUSD 6.78
2024-12-31USD 28,754mUSD 480mUSD 0.38
2023-12-31USD 27,116mUSD 5,665mUSD 4.50
2022-12-31USD 27,281mUSD 4,592mUSD 3.64

Valuation context

This release does not quote price-based multiples because it does not include synchronized market prices. A financial denominator must be paired with a clearly dated market value.

MeasureInterpretation
P/EPrice divided by EPS; identify annual, trailing or forward basis.
P/S & P/BMarket capitalization divided by sales or book equity.
EV / EBITDAEnterprise value and EBITDA need consistent definitions.
FCF yieldFree cash flow divided by dated market capitalization.

A sector median is descriptive, not a fair-value estimate. Explore sector context ↗

Selected filing notes

10-KFiled 2026-02-24Period 2025-12-31

GILD filed this 10-K on 2026-02-24 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

Read SEC original ↗

Related research

Risks & what to monitor

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates